Roche scores an un­usu­al ‘break­through’ at the FDA for an autism drug

The team at Roche’s Basel-based un­der­dog R&D group pRED has some­thing to cheer about to­day. The FDA has des­ig­nat­ed their autism drug RG7314 (balo­vap­tan) as a “break­through” ther­a­py wor­thy of VIP treat­ment at the agency.

Over­shad­owed by Genen­tech (gRED) over the past 9 years, Roche $RHH­BY has been pump­ing mon­ey in­to the Basel group for years, with lit­tle to show for it af­ter a ma­jor re­struc­tur­ing that left John Reed in charge.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER